Keytruda (pembrolizumab)

pCPA File Number: 22035
Negotiation Status:
Under consideration for negotiation
Indication(s):
For the adjuvant treatment of adult patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions
Sponsor/Manufacturer:
Merck Canada Inc.
CADTH Project Number:
PC0273
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable